Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: A survey of the prospective ELCAPA (ELderly CAncer PAtients) cohort.


Journal

Journal of geriatric oncology
ISSN: 1879-4076
Titre abrégé: J Geriatr Oncol
Pays: Netherlands
ID NLM: 101534770

Informations de publication

Date de publication:
05 2020
Historique:
received: 10 01 2019
revised: 02 06 2019
accepted: 30 07 2019
pubmed: 26 8 2019
medline: 29 7 2021
entrez: 26 8 2019
Statut: ppublish

Résumé

Because of comorbidities and polypharmacy, older patients with cancer have a greater risk of iatrogenic events. We aimed to characterize potential drug-drug interactions (PDIs) and the risk of unplanned hospitalization in older patients with cancer treated with antineoplastic agents (ANAs). We analyzed all older patients (≥70 years) from the prospective ELCAPA cohort referred for geriatric assessment (2007-2014) prior to treatment with ANA at Henri Mondor Hospital (Créteil, France). PDIs were identified using Lexicomp®, and Theriaque® for French medications. Factors associated with PDIs, and association between PDIs and unplanned hospitalization in the 6 months following geriatric assessment were analyzed using ordered multivariate logistic regression (MLR). We included 442 patients (median [interquartile range] age: 77 years [74-80]); number of medications/patient/day: 6 [3-8]); ECOG-PS ≤ 2: 79%; metastasis: 70%). Most patients had a digestive tract cancer (colorectal: 22%; upper digestive tract: 23%). We identified 1742 PDIs; 76.5% of patients had ≥1 PDI; 13% of the PDIs involved an ANA. In a multivariate analysis, cardiovascular disorders (ischemic heart disease, heart failure, atrial fibrillation and/or arterial hypertension) were independently associated with PDIs (p < .001, after adjustment for polypharmacy and tumor site/stage). A high number of PDIs between two daily medications was independently associated with the risk of unplanned hospitalization (adjusted-odds ratio [95% confidence interval] per PDI: 1.05 [1.00;1.11], p = .05), while polypharmacy was not. Patients with cardiovascular comorbidities were more likely to have a PDI. A higher number of PDIs may be an independent risk factor for early unplanned hospitalization.

Sections du résumé

BACKGROUND
Because of comorbidities and polypharmacy, older patients with cancer have a greater risk of iatrogenic events. We aimed to characterize potential drug-drug interactions (PDIs) and the risk of unplanned hospitalization in older patients with cancer treated with antineoplastic agents (ANAs).
METHODS
We analyzed all older patients (≥70 years) from the prospective ELCAPA cohort referred for geriatric assessment (2007-2014) prior to treatment with ANA at Henri Mondor Hospital (Créteil, France). PDIs were identified using Lexicomp®, and Theriaque® for French medications. Factors associated with PDIs, and association between PDIs and unplanned hospitalization in the 6 months following geriatric assessment were analyzed using ordered multivariate logistic regression (MLR).
RESULTS
We included 442 patients (median [interquartile range] age: 77 years [74-80]); number of medications/patient/day: 6 [3-8]); ECOG-PS ≤ 2: 79%; metastasis: 70%). Most patients had a digestive tract cancer (colorectal: 22%; upper digestive tract: 23%). We identified 1742 PDIs; 76.5% of patients had ≥1 PDI; 13% of the PDIs involved an ANA. In a multivariate analysis, cardiovascular disorders (ischemic heart disease, heart failure, atrial fibrillation and/or arterial hypertension) were independently associated with PDIs (p < .001, after adjustment for polypharmacy and tumor site/stage). A high number of PDIs between two daily medications was independently associated with the risk of unplanned hospitalization (adjusted-odds ratio [95% confidence interval] per PDI: 1.05 [1.00;1.11], p = .05), while polypharmacy was not.
CONCLUSION
Patients with cardiovascular comorbidities were more likely to have a PDI. A higher number of PDIs may be an independent risk factor for early unplanned hospitalization.

Identifiants

pubmed: 31445850
pii: S1879-4068(19)30005-0
doi: 10.1016/j.jgo.2019.07.023
pii:
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

586-592

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Guillaume Beinse (G)

AP-HP, Henri-Mondor Hospital, Department of Internal and Geriatric Medicine, Sud-Val-de-Marne Geriatric Oncology Unit, Créteil, France; AP-HP, Henri-Mondor Hospital, Departement of Drug Development, Clinical Pharmacology in Oncology, France.

Delphine Reitter (D)

AP-HP, Henri-Mondor Hospital, Department of Pharmacy, Créteil, France.

Lauriane Segaux (L)

University Paris-Est, Paris Est Créteil University (UPEC), CEpiA (Clinical Epidemiology and Ageing), EA 7376-IMRB, Créteil, France; AP-HP, Henri-Mondor Hospital, Department of Public Health, Clinical Research Unit (URC-Mondor), Créteil, France.

Muriel Carvahlo-Verlinde (M)

AP-HP, Henri-Mondor Hospital, Department of Pharmacy, Créteil, France.

Benoit Rousseau (B)

AP-HP, Henri-Mondor Hospital, Departement of Drug Development, Clinical Pharmacology in Oncology, France; AP-HP, Henri-Mondor Hospital, Department of Medical Oncology, Créteil, France.

Christophe Tournigand (C)

AP-HP, Henri-Mondor Hospital, Departement of Drug Development, Clinical Pharmacology in Oncology, France; AP-HP, Henri-Mondor Hospital, Department of Medical Oncology, Créteil, France.

Tristan Cudennec (T)

AP-HP, Ambroise Paré Hospital, Department of Geriatrics, Boulogne-Billancourt, France.

Marie Laurent (M)

AP-HP, Henri-Mondor Hospital, Department of Internal and Geriatric Medicine, Sud-Val-de-Marne Geriatric Oncology Unit, Créteil, France; University Paris-Est, Paris Est Créteil University (UPEC), CEpiA (Clinical Epidemiology and Ageing), EA 7376-IMRB, Créteil, France.

Pascaline Boudou-Rouquette (P)

AP-HP, Cochin Hospital, Department of Medical Oncology, ARIANE, Paris, France.

Elena Paillaud (E)

University Paris-Est, Paris Est Créteil University (UPEC), CEpiA (Clinical Epidemiology and Ageing), EA 7376-IMRB, Créteil, France; AP-HP, Hopital Europeen Georges Pompidou, Department of Geriatrics, Paris, France.

Florence Canouï-Poitrine (F)

University Paris-Est, Paris Est Créteil University (UPEC), CEpiA (Clinical Epidemiology and Ageing), EA 7376-IMRB, Créteil, France; AP-HP, Henri-Mondor Hospital, Department of Public Health, Clinical Research Unit (URC-Mondor), Créteil, France.

Philippe Caillet (P)

University Paris-Est, Paris Est Créteil University (UPEC), CEpiA (Clinical Epidemiology and Ageing), EA 7376-IMRB, Créteil, France; AP-HP, Hopital Europeen Georges Pompidou, Department of Geriatrics, Paris, France. Electronic address: philippe.caillet@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH